Insider buying
~$40K9,891 sh @ $4.04
Traded Jun 11 · filed 1 day later
The CEO of Treace Medical Concepts paid $40K out of pocket for Treace Medical Concepts shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 11, 2026 · Filed Jun 11, 2026
The CEO of Treace Medical Concepts paid $93K out of pocket for Treace Medical Concepts shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$92,541
Shares × reported transaction price
$25K–$100K
+0.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 9 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.7% of the CEO's reported total pay for fiscal 2025 ($5.41M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-06. The proxy names John T. Treace as CEO for that year. A size comparison, not a judgement
34 days after results of May 8, 2026, 57 days before results of Aug 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $3.91 on Jun 11, 2026, 226% above its 52-week low and 49% below its high, after a 120% rise over the previous 30 trading days
52-week range $1.20 (Mar 30, 2026) to $7.70 (Aug 22, 2025), 42% of the way up, from 250 adjusted closes. 30 trading days earlier: $1.78 on Apr 29, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Apr 11, 2025 in the U.S. District Court, M.D. Florida. A filing is an allegation, not a finding.
McCluney v. Treace Medical Concepts, Inc., docket 3:25-cv-00390, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.2% | +0.4% | −1.6% |
| 30 days | +12.8% | +1.0% | +11.8% |
| 90 days | +7.1% | +2.2% | +5.0% |
Past results only. Not a forecast.
Insider buying
Traded Jun 11 · filed 1 day later
The CEO of Treace Medical Concepts paid $40K out of pocket for Treace Medical Concepts shares.
Insider buying
Traded Jun 10 · filed 2 days later
The CEO of Treace Medical Concepts paid $59K out of pocket for Treace Medical Concepts shares.
Insider buying
Traded Jun 10 · filed 1 day later
The CEO of Treace Medical Concepts paid $118K out of pocket for Treace Medical Concepts shares.
John T. Treace, Chief Executive Officer's past purchases, 90 days after disclosure: 5 buys, median +31.0 pts vs S&P 500, beat it 4 of 5 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.